|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the association of LpPLA2 activity and ApoC3 LOF mutations and incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities (ARIC) study.
|
26117401 |
2015 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A DNA polymorphism of the apolipoprotein C-III gene in extracoronary atherosclerosis.
|
3345637 |
1988 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures: MESA (The Multi-Ethnic Study of Atherosclerosis).
|
29540426 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated how the presence of apoC-III affects the association between HDL and early stages of atherosclerosis measured as carotid intima-media thickness (cIMT).
|
29351856 |
2018 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have recently isolated and characterized the human apo A-I gene and have shown that apo A-I and apolipoprotein C-III (apo C-III) genes are physically linked and that a polymorphism (of unknown frequency in the general population) of the apo A-I gene is inherited as a mendelian trait linked to premature atherosclerosis in an affected family (not the same polymorphism as has previously been reported to be associated with hypertriglyceridaemia).
|
6314145 |
1983 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.
|
30949716 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A synergistic interaction between the apolipoprotein C-III and the LDL receptor defects produced large quantities of VLDL and LDL and enhanced the development of atherosclerosis.
|
8994037 |
1997 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, AR ameliorated atherosclerosis via the regulation of hepatic lipid metabolism, and AR also contributed to the activation of PPAR-alpha, APOA1, APOA2 and APOC3.
|
25979856 |
2015 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have recently reported that the human apolipoprotein A-I (apoA-I) and apolipoprotein C-III (apoC-III) genes are physically linked and that the presence of a DNA insertion in the apoA-I gene is correlated with apoA-I-apoC-III deficiency in patients with premature atherosclerosis.
|
2989400 |
1985 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Global severity of atherosclerosis at the first angiography was weakly associated with genotypes of the apoCIII-C/T1100 polymorphism, presence of the T1100 allele being associated with 53% lower median score (1.6 vs 0.75; p = 0.09).(ABSTRACT TRUNCATED AT 400 WORDS)
|
7834891 |
1994 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but also participates in the atherosclerotic lesion formation and several other pathological processes involved in atherosclerosis.
|
27770802 |
2016 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship between the S2 allele of the SstI polymorphism and plasma apoCIII or TG and their roles in atherosclerosis are also unknown.
|
29162127 |
2017 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphisms in the apolipoprotein C-III and insulin genes and atherosclerosis.
|
3911967 |
1985 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
|
19074352 |
2008 |
|
Atherosclerotic lesion
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but also participates in the atherosclerotic lesion formation and several other pathological processes involved in atherosclerosis.
|
27770802 |
2016 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
BREAST CANCER, SOMATIC
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.
|
10360669 |
1999 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present deletion map indicates that three distinct regions at 11q23.1 may be involved in breast cancer development; one between the markers D11S1294 and D11S1818, a second close to APOC-3, and a third that is possibly the ATM-gene itself.
|
9071570 |
1997 |
|
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Previous studies on breast carcinomas by Winqvist et al (Cancer Res 55: 2660-2664) have indicated that a survival factor gene is located in band 11q23, and that the highly informative microsatellite polymorphism at the APOC3 locus would be a suitable tool to perform more extensive LOH studies.
|
10360669 |
1999 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
To examine cancer-related allelic loss in the region between D11S940 and APOC3, we used 17 polymorphic markers and allotyped 28 lung cancer-derived cell lines and their corresponding matched lymphoblastoid cell lines.
|
10337999 |
1999 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease.
|
31111320 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mixed dyslipidemia, characterized by elevated triglyceride and apoC-III levels and low HDL cholesterol level, with or without elevated LDL cholesterol, increases cardiovascular disease risk and is commonly treated with combined statin and fibrate therapy.
|
22236405 |
2012 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS).
|
29555504 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
|
31449060 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Increasing evidence has shown that loss-of-function mutations in APOC3 is associated with reduction in plasma triglycerides levels and will confer a benefit in patients at high risk for cardiovascular disease.
|
27624799 |
2016 |